Business Wire

City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for Geographic Atrophy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced that it has entered ...
Ars Technica

Tiny, 45 base long RNA can make copies of itself

There are plenty of unanswered questions about the origin of life on Earth. But the research community has largely reached consensus that one of the key steps was the emergence of an RNA molecule that ...
New Scientist

RNA strand that can almost self-replicate may be key to life's origins

According to the RNA world hypothesis, life began when RNA molecules evolved the ability to make more copies of themselves. Now we have discovered an RNA molecule that is almost capable of this – it ...
Phys.org

Scientists use RNA nanotechnology to program living cells, opening a new path for cancer cure

Scientists at Rutgers University–Newark have developed a first-of-its-kind RNA-based nanotechnology that assembles itself inside living human cells and can be programmed to stop propagation of harmful ...
Medical Xpress

RNA molecule discovery could lead to potential new breast cancer therapy

QIMR Berghofer scientists have discovered a cancer-fighting RNA molecule that could hold the key to a new way of treating the most common form of breast cancer. The team are developing their findings ...
BioWorld

Genentech licenses Sanegene’s RNAi asset in $1.7B deal

Genentech Inc. is paying $200 million up front and up to $1.5 billion in milestone payments to license one of Suzhou Sanegene Bio Inc.’s RNAi programs. Metabolic and autoimmune-focused Sanegene did ...
FierceBiotech

Roche's return to RNA continues with $1.7B deal for Sanegene program

Roche is continuing its return to the RNA space by paying $200 million for the worldwide license to one of SanegeneBio’s programs. The companies didn’t specify which indication the program is focused ...
GEN

Genentech, SanegeneBio Launch Up-to-$1.7B RNAi Collaboration

A SanegeneBio researcher at work in the company's lab. Genentech, a member of the Roche Group, will apply SanegeneBio’s RNA interference (RNAi) platform to develop one of the company’s RNAi programs ...
News Medical

What Is the Difference Between siRNA and shRNA Knockdown Methods?

Gene knockdown is a common method for studying gene function by reducing messenger ribonucleic acid (mRNA) levels without altering the deoxyribonucleic acid (DNA). Among the available techniques, RNA ...
FiercePharma

Alnylam lays out $250M to equip flagship facility with cutting-edge siRNA production tech

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship manufacturing facility in Massachusetts. Alnylam plans to spend $250 million in a ...